ERBB2 and breast carcinoma: Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) breast cancer is the most common subtype, characterized by heterogeneous neoadjuvant chemotherapy (NAC) responses and low pCR rates.